NeuroVive Pharmaceutical, the mitochondrial medicine company, today announced that the company has recruited Michele Tavecchio, PhD, as senior scientist.
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the company has recruited Michele Tavecchio, PhD, as senior scientist.
In his new role, Dr. Tavecchio will be leading R&D activities related to
NeuroVive’s discovery programs, working closely with CSO Eskil Elmér,
CMO Magnus Hansson, and the core research team of scientists at
NeuroVive. Dr. Tavecchio holds a PhD in Cancer Pharmacology from the
Mario Negri Institute for Pharmacological Research in Milan and has
authored over 20 scientific publications. Most recently he comes from a
position as Associate Staff Scientist at Wistar Institute in
Philadelphia, USA, where his research activities have been focused on
the involvement of ciclophilin D in various aspects of metabolic
diseases and cancer.
“We are extremely happy to be able to add Dr. Tavecchio to our research
team. His research expertise in the ciclophilin D area and related
metabolic effects fits hand in glove with NeuroVive’s project portfolio.
In combination with his extensive knowledge within the oncology area,
Dr. Tavecchio’s primary task for NeuroVive will be to explore new
therapeutic opportunities for the company’s ciclophilin inhibitor
compounds”, said Eskil Elmér, CSO NeuroVive.
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The
company is committed to the discovery and development of medicines that
preserve mitochondrial integrity and function in areas of unmet medical
need. The company’s strategy is to take drugs for rare diseases through
clinical development and into the market. The strategy for projects
within larger indications outside the core focus area is out-licensing
in the preclinical phase. NeuroVive enhances the value of its projects
in an organization that includes strong international partnerships and a
network of mitochondrial research institutions, as well as expertise
with capacities within drug development and production.
NeuroVive has a project in early clinical phase II development for the
prevention of moderate to severe traumatic brain injury (NeuroSTAT®).
NeuroSTAT has orphan drug designation in Europe and in the US. The R&D
portfolio consists of several late stage research programs in areas
ranging from genetic mitochondrial disorders to neurological and
metabolic diseases such as NASH.
NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share
is also traded on the OTCQX Best Market in the US (OTC: NEVPF).
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
This information is information that NeuroVive Pharmaceutical AB (publ)
is obliged to make public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication, through the agency of the
contact person set out above, at 08:30 a.m. CET on November 8, 2016.
This information was brought to you by Cision http://news.cision.com